top of page
The Professional Network for Healthcare Experts
Zealand Pharma begins Phase 3 ZUPREME programme for petrelintide in obesity
Zealand Pharma and Roche have started the global Phase 3 ZUPREME programme evaluating once-weekly petrelintide as a treatment for people with overweight or obesity.
nuaxia
Sep 242 min read
Roche’s Genentech licenses Hanmi obesity candidate HM17321 in deal worth up to $2.3 billion
The agreement gives Genentech ex-South Korea rights to a Phase I non-incretin UCN2 analogue designed to reduce weight while preserving lean body mass, adding a differentiated mechanism to Roche’s growing cardiometabolic pipeline.
nuaxia
Aug 253 min read
Kalohexis Files Confidentially for IPO to Advance Obesity and Cachexia Pipeline
The clinical-stage biotech plans to use a potential public listing to accelerate development of melanocortin-based therapies targeting obesity and cancer cachexia.
nuaxia
Jul 93 min read
Lilly’s Oral GLP-1 Foundayo Wins FDA Approval, Intensifying Obesity Drug Market Competition
New oral weight-loss treatment enters the market as competition with Novo Nordisk’s oral Wegovy accelerates.
nuaxia
Apr 21 min read
NMPA Approves Ecnoglutide for Chronic Weight Management in Adults with Overweight or Obesity
China authorises the first cAMP-biased GLP-1 receptor agonist for obesity, following robust Phase III SLIMMER trial results.
nuaxia
Mar 91 min read
bottom of page